News

iTeos Therapeutics to Present at 2019 Wedbush PacGrow Healthcare Conference

Gosselies, Belgium and Cambridge, MA – August 7, 2019 – iTeos Therapeutics SA, a privately-held biotechnology company developing novel cancer immunotherapies, today announced that Michel Detheux, Ph.D., President and Chief Executive Officer of iTeos, will present at the 2019 Wedbush PacGrow Healthcare Conference on Wednesday, August 14, 2019 at 9:45 a.m. ET in New York, NY.

About iTeos Therapeutics

Read more

iTeos Therapeutics to Present at UBS Global Healthcare Conference

Gosselies, Belgium and Cambridge, MA – May 13, 2019 – iTeos Therapeutics SA, a privately-held biotechnology company developing novel cancer immunotherapies, today announced that Michel Detheux, Ph.D., President and Chief Executive Officer of iTeos, will present at the UBS Global Healthcare Conference on Monday, May 20, 2019 at 11:30 a.m. ET in New York, NY.

Read more

iTeos Therapeutics Announces Eight Data Presentations for A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at AACR Annual Meeting 2019

Gosselies, Belgium and Cambridge, MA – March 29, 2019 – iTeos Therapeutics SA, a privately-held biotechnology company developing novel cancer immunotherapies, today announced that it will present data on the efficacy of its innovative and differentiated A2A receptor antagonist, EOS100850, as well as its human antibody directed against TIGIT, EOS884448, in eight posters at the upcoming American Association of Cancer Research (AACR) Annual Meeting 2019, taking place from March 29 - April 3, 2019 in Atlanta, Georgia. 

Read more